Clinical trials: Blood Plasma Therapy
Pyoderma Gangrenosum
Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum
Pyoderma gangrenosum (PG) is a chronic inflammatory condition with severe painful ulcers. We hypothesize that Platelet-rich plasma(PRP) therapy derived from patient's own blood has a high concentration of endogenous growth…
- Trial name
- NCT05984654
- Testing
- Platelet rich plasma therapy
- Where
- United States
- Sponsor
- Ohio State University
Multiple Myeloma
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
The outcomes in patients with relapsed or refractory multiple myeloma refractory to triple-therapy remain poor. These patients are eligible for chimeric antigen receptor T-cells (CAR-T), which rely on redirecting autologous…
- Trial name
- NCT07200102
- Testing
- Selinexor
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Relapsed/Refractory Multiple Myeloma
Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of bispecific BCMA-GPRC5D CAR-T cells in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy.
- Trial name
- NCT06515262
- Testing
- Anti-BCMA-GPRC5D CAR-T cells infusion
- Where
- China
- Volunteers
- 10 people
- Sponsor
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Acute Myeloid Leukemia, Non-hodgkin's Lymphoma
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
A Study of CD 70 CAR T for patients with CD70 positive malignant hematologic diseases
- Conditions
- Acute Myeloid Leukemia, Non-hodgkin's Lymphoma, Multiple Myeloma
- Trial name
- NCT04662294
- Testing
- CD70 CAR T-cells
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Zhejiang University
Multiple Myeloma
Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma
This is an open-label, non-randomized Phase 1 study evaluating the role of two regimens: A) Nivolumab in combination with Pomalidomide and low dose dexamethasone and B) Nivolumab + Elotuzumab + Pomalidomide + dexamethasone in the…
- Trial name
- NCT03023527
- Testing
- Nivolumab, Pomalidomide, Dexamethasone
- Where
- 12 sites in Spain
- Volunteers
- 6 people
- Sponsor
- PETHEMA Foundation
Erythropoietic Protoporphyria (EPP), X Linked Erythropoietic Protoporphyria
Effect of Isoniazid on Protoporphyrin Levels in Erythropoietic Protoporphyria
In erythropoietic protoporphyria there is an accumulation of protoporphyrin IX (PPIX) in the plasma and liver. The reason it builds up is either the last step to make heme, insertion of iron into PPIX, is rate limiting or there…
- Trial name
- INHEPP (NCT01550705)
- Testing
- Isoniazid
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Utah
Multiple Myeloma
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies
This study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM). Sometimes MM might improve at first, but then gets resistant to the treatment and starts growing again…
- Trial name
- NCT06592222
- Testing
- Elranatamab, Standard of care
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Pfizer
Non-Small Cell Lung Carcinoma, Small Cell Lung Cancer
Detection of Plasma DNA in Non Small Cell and Small Cell Lung Cancer Patients
The majority of lung cancer patients have a tumor-derived genetic alteration in circulating plasma DNA that could be exploited as a diagnostic tool.
- Trial name
- NCT00213798
- Testing
- Biopsy samples
- Where
- 4 sites in France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Multiple Myeloma
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, to…
- Trial name
- Talisman (NCT06500884)
- Testing
- Talquetamab, Prophylaxis A, Prophylaxis B
- Where
- 38 sites in United States, Brazil and 5 more
- Volunteers
- 210 people
- Sponsor
- Janssen Research & Development, LLC
Osteoarthritis, Knee
Use of Fresh Platelet Rich Plasma With Concentrated Leukocytes or Fresh Platelet Rich Plasma Without Concentrated Leukocytes in the Treatment of Knee Cartilage Degeneration: a Randomized Controlled Trial
The aim of the study is to compare the triple infiltration of Fresh Platelet Rich Plasma with concentrated Leukocytes against triple infiltration of Fresh Platelet Rich Plasma Without Concentrated Leukocytes in the treatment of…
- Trial name
- PRP019 (NCT04187183)
- Testing
- Fresh Platelet Rich Plasma with leukocyte, Fresh Platelet Rich Plasma without leukocyte
- Where
- Italy
- Volunteers
- 132 people
- Sponsor
- Istituto Ortopedico Rizzoli
Alpha 1-Antitrypsin Deficiency, Emphysema
Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema
Phase 2 study to compare SAR447537 (INBRX-101) to plasma derived A1PI therapy in adults with AATD emphysema
- Trial name
- ELEVAATE (NCT05856331)
- Testing
- SAR447537, Zemaira
- Where
- 65 sites in United States, Australia and 6 more
- Volunteers
- 99 people
- Sponsor
- Sanofi
Multiple Myeloma
Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma
The purpose of this study is to evaluate the safety and efficacy of the association of Melphalan/Prednisone/Revlimid (MPR) as induction treatment for newly diagnosed myeloma patients over age 65 or those under 65 years who refuse…
- Trial name
- NCT00396045
- Testing
- Revlimid (CC-5013)
- Where
- 9 sites in Italy
- Volunteers
- 54 people
- Sponsor
- University of Turin, Italy
Multiple Myeloma
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
The study consists of three parts: Part 1: The primary purpose of this part aims to evaluate the safety, tolerability, and clinical activity of escalating doses of single agent belantamab in participants with refractory multiple…
- Trial name
- DynaMMic-1 (NCT05714839)
- Testing
- Belantamab, Belantamab mafodotin, Pomalidomide
- Where
- 44 sites in United States, Argentina and 11 more
- Volunteers
- 123 people
- Sponsor
- GlaxoSmithKline
Waldenstrom Macroglobulinemia
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia
Current therapies for Recurrent or Refractory Waldenstrom's Macroglobulinemia provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment…
- Trial name
- NCT00003512
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Sponsor
- Burzynski Research Institute
Covid19, Cytokine Release Syndrome
Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan
Beyond supportive care, there are currently no proven treatment options for coronavirus disease (COVID-19) and related pneumonia, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).Investigators have seen…
- Conditions
- Covid19, Cytokine Release Syndrome, Critical Illness, ARDS
- Trial name
- NCT04492501
- Testing
- Therapeutic Plasma exchange, Convalescent Plasma, Tocilizumab
- Where
- Pakistan
- Volunteers
- 600 people
- Sponsor
- UNICEF
Multiple Myeloma, Amyloidosis
Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.
Captisol Enabled Melphalan, is a new formulation of the standard of care melphalan chemotherapy that in packaged in an inactive substance that is believed to help the chemotherapy be more stable (meaning that it doesn't lose its…
- Trial name
- NCT02909036
- Testing
- Melphalan, Pegfilgrastim, Autologous Hematopoietic Progenitor Cell Transplant
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Healthy
Comparative Bioavailability Study of Lisinopril Tablets, 10 mg
The purpose of this study is to compare the bioavailability of Par Lisinopril 10 mg Tablets and IPR Pharmaceuticals, Inc. Zestril (R).
- Trial name
- NCT01375244
- Testing
- Lisinopril, Zestril
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Par Pharmaceutical, Inc.
Therapeutic Plasma Exchange
IMPACT OF THERAPEUTIC PLASMA EXCHANGE ON ACQUIRED VACCINAL ANTI-SARS-CoV-2 ANTIBODIES.
Context: Therapeutic plasma exchange is an extracorporeal blood purification technique that removes pathogenic substances (including antibodies) from plasma. This technique also combines an immunomodulatory effect.
- Trial name
- NCT05191394
- Testing
- Evolution of antibodies titre
- Where
- Belgium
- Volunteers
- 15 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Multiple Myeloma
The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients
To evaluate the efficacy and safety of investigational drug Colchicine combined with conventional lenalidomide based therapy in multiple myeloma subjects who had received first-line therapy (including Chimeric antigen receptor…
- Trial name
- NCT05802992
- Testing
- Colchicine, Lenalidomide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital of Nantong University
Anal Fistula
Role of Autologous Platelet Rich Plasma(PRP) Injection and Platelet Rich Fibrin Glue(PRFG) Interposition for Treatment of Anal Fistula
To evaluate the autologous platelet rich plasma and platelet rich fibrin glue effect on the treatment of anal fistula To asses role of platelet rich plasma and platelet rich fibrin glue in decreasing recurrence of perianal fistula
- Trial name
- NCT06092398
- Testing
- PRP and PRFG in treatment of anal fistula
- Volunteers
- 60 people
- Sponsor
- Assiut University